David Miklos Md Phd On

Quick Overview: Clinical Impact of H-Y Alloimmunization by For patients who experience graft-versus-host disease after transplant and do not respond to corticosteroids, ibrutunib leads to a ... Our live event focused on how to navigate life and decisions after getting diagnosed with cancer, specifically non-Hodgkin ...

David Miklos Md Phd On - Detailed Overview & Context

Clinical Impact of H-Y Alloimmunization by For patients who experience graft-versus-host disease after transplant and do not respond to corticosteroids, ibrutunib leads to a ... Our live event focused on how to navigate life and decisions after getting diagnosed with cancer, specifically non-Hodgkin ...

Photo Gallery

The significance of increased clonal hematopoiesis mutation allele frequency after CAR-T therapy

Durability & safety of CD22-directed CAR T-cells for patients with LBCL progressing on CD19 CAR-T

Clinical Impact of H-Y Alloimmunization by David Miklos, MD, PhD

David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease

David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study

Dr. Miklos on the Results of the ZUMA-2 Trial in MCL

CAR T Therapy: Clinical Trials and Updates | Dr. David Miklos, Stanford | The Patient Story

What to Do After a Cancer Diagnosis | For Non-Hodgkin Lymphoma Patients and Caregivers

David Miklos, MD, on developing an orphan drug for a small population of patients

Ongoing CAR-T stewardship: monitoring the long-term safety of these therapies & reassuring patients

David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD

Dr. David Miklos_Car-T

View Main Result

The significance of increased clonal hematopoiesis mutation allele frequency after CAR-T therapy

The significance of increased clonal hematopoiesis mutation allele frequency after CAR-T therapy

David Miklos

Durability & safety of CD22-directed CAR T-cells for patients with LBCL progressing on CD19 CAR-T

Durability & safety of CD22-directed CAR T-cells for patients with LBCL progressing on CD19 CAR-T

In this video,

Clinical Impact of H-Y Alloimmunization by David Miklos, MD, PhD

Clinical Impact of H-Y Alloimmunization by David Miklos, MD, PhD

Clinical Impact of H-Y Alloimmunization by

David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease

David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease

For patients who experience graft-versus-host disease after transplant and do not respond to corticosteroids, ibrutunib leads to a ...

David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study

David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study

Dr

Dr. Miklos on the Results of the ZUMA-2 Trial in MCL

Dr. Miklos on the Results of the ZUMA-2 Trial in MCL

David Miklos

CAR T Therapy: Clinical Trials and Updates | Dr. David Miklos, Stanford | The Patient Story

CAR T Therapy: Clinical Trials and Updates | Dr. David Miklos, Stanford | The Patient Story

Dr

What to Do After a Cancer Diagnosis | For Non-Hodgkin Lymphoma Patients and Caregivers

What to Do After a Cancer Diagnosis | For Non-Hodgkin Lymphoma Patients and Caregivers

Our live event focused on how to navigate life and decisions after getting diagnosed with cancer, specifically non-Hodgkin ...

David Miklos, MD, on developing an orphan drug for a small population of patients

David Miklos, MD, on developing an orphan drug for a small population of patients

Dr

Ongoing CAR-T stewardship: monitoring the long-term safety of these therapies & reassuring patients

Ongoing CAR-T stewardship: monitoring the long-term safety of these therapies & reassuring patients

David Miklos

David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD

David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD

Dr

Dr. David Miklos_Car-T

Dr. David Miklos_Car-T

Dr. David Miklos_Car-T

David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies

David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies

Dr

Developments in CAR T treatments for adult patients

Developments in CAR T treatments for adult patients

Dr David Miklos

Dr. Miklos on Development Process for KTE-X19 in MCL

Dr. Miklos on Development Process for KTE-X19 in MCL

David Miklos

2019 MCHRI Symposium - David Miklos

2019 MCHRI Symposium - David Miklos

David

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients

Dr

Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision

Dr. Miklos on Alternative Options to KTE-X19 in MCL, While Awaiting FDA Decision

David Miklos

Despite toxicities, ibrutinib is beneficial for treatment-resistant graft-vs.-host disease

Despite toxicities, ibrutinib is beneficial for treatment-resistant graft-vs.-host disease

host disease,